Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Astellas of Japan and Cytomx of the US will deploy the latter’s Probody bispecific technology to design therapeutics that remain inactive until triggered by proteases in the tumor microenvironment, so that they bind selectively to tumors and leave healthy tissue alone.
Adequate funding and joined-up global cooperation are two top priorities needed to combat COVID-19, a panel of pharma executives told this year’s BIO-Europe Spring.
Bayer and Curadev entered a research collaboration and license agreement to develop novel STING antagonists targeting inflammatory disease.
AGC of Japan is offering to buy cell and gene therapy specialist MolMed SPA in a deal worth up to €240m and backed by the biotech’s biggest shareholder, Silvio Berlusconi’s Fininvest.
Sweden is testing ‘pull incentives’ in hopes of finding viable reward mechanisms that would ensure adequate access to important antibiotics to meet the Scandinavian country’s domestic internal needs.
Designers of the UK’s experimental antibiotic payment system aim to identify two drugs later this year which will then undergo a novel technology assessment in 2021.